openPR Logo
Press release

Nanion’s automated patch clamp platforms show unparalleled results using stem cell derived cardiomyocytes

09-19-2011 07:47 AM CET | Science & Education

Press release from: Nanion Technologies

Munich, Germany, September 16, 2011; The Patchliner and the SyncroPatch 96 have successfully been used for compound analysis under current- and voltage clamp recording conditions using different stem cell-derived cardiomyocytes. The exceptional cell-platform-compatibility and the unique experimental possibilities offered by Nanion’s platforms open up whole new avenues for compound safety testing.

Pluripotent stem cell-derived cardiomyocytes have tremendous potentials for cardiac safety and efficacy testing of drug candidates. By offering an authentic cellular environment they are closer to the actual physiological situation compared to cell lines with over-expressed ion channels. All Nanion’s patch clamp platforms, the Port-a-Patch, the Patchliner and the SyncroPatch 96, show exceptional compatibility with stem cell-derived cardiomyocytes provided by Axiogenesis, CDI and Geron/GE Healthcare.

In a joint publication of Nanion and Axiogenesis (Journal of Biomolecular Screening, 2011 July 20), drug-induced modulation of cardiac action potentials using the Port-a-Patch and Patchliner were shown for the first time. Stem cell-derived cardiomyocytes have also been investigated on the SyncroPatch 96, recording from 96 cells in parallel under voltage clamp conditions. Stable whole-cell recordings were obtained with high success rates and expected cardiac currents were recorded (K+, Ca2+, Na+).
Ralf Kettenhofen, Senior Scientist of Axiogenesis, Cologne, Germany, says:
“At Axiogenesis, we were very impressed of the high success rates quickly obtained with Nanion’s platforms. In our view, the combination of an in vitro cardiac cell model together with higher throughput patch clamp screening technology such as the Patchliner, allows for a cost effective cardiotoxicity prediction in a physiologically relevant cell system.”

Axiogenesis is a provider of pure rodent embryonic stem cell-derived cardiomyocytes (Cor.At®) which have been proven to be a predictive tool in preclinical cardiac safety assessment and drug discovery and development. The Cor.At® cardiomyocytes will now be complemented by human induced pluripotent stell cell-derived (Cor.4U®) cardiomyocytes, which will be launched in Q1 2012.

Niels Fertig, CEO of Nanion Technologies continues:
“Over the past two years, the interest from the pharmaceutical industry in using stem cell-derived cardiomyocytes for safety testing purposes has grown dramatically. To meet this need we have developed our platforms to fit experimental requirements and industry quality standards. It is up to the user to decide: routine analysis in voltage clamp mode, or investigating the compound effect on action potentials since both screening modes are possible. No other APC platform on the market can compete with that at today’s date.”

About Nanion
Nanion Technologies GmbH is a German, private, limited company, founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich, Germany. Nanion’s team has developed and globally established three successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.
Nanion's high quality instruments employ planar patch clamp chips which replace the traditional glass pipette used in the conventional patch clamp technique. In 2009 Nanion was awarded the German Founders Award (Gründerpreis), and the Innovation Prize Step Award. Next year, Nanion celebrates its 10th anniversary.
Contact details:
Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: info@nanion.de, Web: www.nanion.de

About Axiogenesis
Axiogenesis is a biotechnology company located in Cologne, Germany. One focus of Axiogenesis is the generation and production of pure in vitro differentiated cells that display normal physiological properties. Axiogenesis‘ cells are either of rodent embryonic stem cell or human induced pluripotent stem cell origin. These cells are then used to develop novel assays for pharmacology and safety screening in the pharmaceutical, chemical, and cosmetics industries.
Pure rodent ES cell-derived (CorAt®) cardiomyocytes are available in unlimited amounts, can be shipped frozen overnight, and are quality controlled showing no lot-to-lot variation. Protocols and applications include but are not limited to cardiac specific cytotoxicity, electrophysiology, GPCR functionality, siRNA transfection and hypertrophy induction. The cells express and use all essential ion channels and K+, Na+, and Ca2+ currents have been recorded in patch clamp experiments. In addition, Cor.At® cardiomyocytes are highly predictive with respect to humans as revealed by the observation of expected effects of known ion channel and GPCR modulators (including hERG blocker) and specific cardiac cytotoxicants. Cor.At® cardiomyocytes have been validated successfully on almost all available instrument and assay platforms encompassing both high content applications like automated patch clamp and high throughput screening systems like fluorescent plate reader.
Using its stem cell technology Axiogenesis has consequently designed its proprietary Clinical Modeling platform utilizing cardiomyocytes with different disease phenotypes. This technology is able to substantially accelerate the drug development process. Axiogenesis is further offering exclusive customization services of cell lines and in house production of cardiomyocytes, endothelial cells, hepatocytes and neuronal cells.
Contact details:
For further information on Axiogenesis and its products please contact:
Felix von Haniel, Phone: +49 (221) 9988 1825, Email: info@axiogenesis.com, web:

Nanion Technologies
Gabrielenstrasse 9
80636 Munich
Germany

Press contact: Cecilia Farre, Marketing Director
Telephone: +49 89218997973
Email: cecilia@nanion.de

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nanion’s automated patch clamp platforms show unparalleled results using stem cell derived cardiomyocytes here

News-ID: 192146 • Views: 991

More Releases from Nanion Technologies

Nanion Starts Shipping the SyncroPatch 384 Patch Engine - a Revolutionary Instru …
The brand-new SyncroPatch 384 Patch Engine (PE) now released by Nanion Technologies propels ion channel drug discovery to a new level. Designed for seamless integration into process-automated drug screening environments, the Patch Engine is equipped with 384 patch clamp amplifiers and an advanced 384 channel liquid handling robot. The SyncroPatch 384PE is the high quality, automated patch clamp system able to finally thrust gold standard electrophysiology from secondary to primary
Nanion Introduces New Product Family: CardioExcyte 96 for Cardiac Toxicity Profi …
Munich, Germany, September 12, 2013; The CardioExcyte 96 is a high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements. The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters. Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very
Nanion Introduces NPC-Certified Cell Lines
Munich, Germany, November 08, 2012; Nanion’s automated patch clamp platforms are known for their high cell compatibility, even for primary cells and stem cells. Nanion now introduces “Nanion Approved Cells”, where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance. The approved cells can be directly purchased through Nanion, so that Nanion’s customers get a complete package of APC platform and
Nanion Acquires the SURFE2R Technology for Transporter Protein Analysis
Nanion acquires the well-established SURFE2R technology, allowing state-of-the-art measurements of transporter protein activity and function. The SURFE2R technology is an excellent enhancement to Nanion’s existing products which until now covered ion channels and nanopores. Nanion Technologies is one of the leading providers of high quality automated patch clamp systems. Nanion’s efficient and versatile products drastically improve the data output in patch clamp-based ion channel screening, safety testing and scientific research. Since

All 5 Releases


More Releases for Axiogenesis

Stem Cells Global Market 2018: Key Players – Aastrom Biosciences, Inc., Advanc …
Stem Cells Industry Description Wiseguyreports.Com Adds “Stem Cells -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database Stem Cell Market research report gives a market insight into the ever progressing and debatable market of Stem Cell Research segmented by type, technology and therapeutic area. Stem Cells by Type are further classified into Adult Stem Cells, Cord Blood Stem Cells, Embryonic Stem Cells and Other. Stem
Global Cell Based Assay Market: Market Estimation, Dynamics, Regional Share, Tre …
Cell Based Assay Market: Cell based assay Market is increased at a significant CAGR owing to rise in funding and investment for the R&D activities. Increase in the prevalence and incidence of chronic diseases such as cancer, drug discovery, increase in the government expenditure, and rise in the adoption of cell-based consumables by various organizations might fuel the cell-based assay market over the forecast period. Moreover, the rise in demand
+18% CAGR Growth Projected in Stem Cell Banking Market to Surpass US$ 7.7 Billio …
The Global Stem Cell Banking Market, by Source Type (Cord Blood and Cord Tissue), by Service Type (Collection and Transportation, Processing, Analysis, and Storage), by Application (Leukemia, Diabetes, Lymphoma, Cerebral Palsy, Thalassemia, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 1,634.7 million in 2016 and is projected to exhibit a CAGR of 18.9%over the forecast period (2017–2025),
Global Induced Pluripotent Stem Cells Market 2017: Key Players: ADDGENE, ALSTEM …
WiseGuyReports published new report, titled “Induced Pluripotent Stem Cells” Report Scope: This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered. For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis; iPSC-derived cell-type-based market
05-08-2017 | Health & Medicine
SA-BRC
Global Induced Pluripotent Stem Cells Market Forecast 2017-2021
Stem cells have been a major focus for research in the past decade. Depending on the potential to differentiate, various types of stem cells are been explored in biotechnology research globally. However limited number of sources of stem cells had impeded the success of various research programs. In 2006, Shinya Yamanaka, Kyoto University, Japan was successful in inducing pluripotency in adult cells. This was a revolutionary discovery that marked the
Nanion Introduces New Product Family: CardioExcyte 96 for Cardiac Toxicity Profi …
Munich, Germany, September 12, 2013; The CardioExcyte 96 is a high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements. The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters. Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very